Evolución de los factores de riesgo cardiovascular en pacientes sometidos a intervención coronaria percutánea

  1. Jael Voces-Álvarez
  2. Díaz Grávalos, Gabriel J.
Journal:
Enfermería clínica

ISSN: 1130-8621

Year of publication: 2015

Volume: 25

Issue: 4

Pages: 171-176

Type: Article

DOI: 10.1016/J.ENFCLI.2015.04.006 DIALNET GOOGLE SCHOLAR

More publications in: Enfermería clínica

Abstract

Aim Controlling cardiovascular risk factors (CVRF) is important for the outcome of interventional practices (percutaneous coronary intervention [PCI]) in ischemic heart disease. The aim is to determine the evolution of the CVRF 6 months after the intervention and their relationship with new events. Method A descriptive study was conducted on a case series. The variables recorded were: age, sex and chronic kidney disease (CKD), as well as total (TC) and HDL cholesterol, systolic (SBP) and diastolic blood pressure (DBP), smoking habit, and body mass index (BMI), before PCI and after 6 months. The occurrence of death or new PCI during the follow-up was considered an independent variable in a logistic regression analysis. A P < .05 was assumed significant. Results A total of 222 cases (75.2% males) were included, with a mean age of 70.2 (SD 11.9) years, of whom 57.7% were hypertensive patients, 55.9% had hyperlipidemia, 50.4% were smokers or ex-smokers, and 28.2% were diabetics. After 6 months, 5% died, and 15.3% needed a new PCI, while 33% of the sample had all the CVRF considered. Decreases were observed in SBP (−3.3 mmHg), DBP (−2.6 mmHg), and TC (−35.2 mg/dl). The emergence of new event was associated with age (OR: 1.06; P = .003) and CKD (OR: 3.7; P = .04). Conclusions There is a high prevalence of CVRF. After 6 months, there was a decrease in blood pressure and TC, although incomplete control of CVRF was found. One fifth of the patients had an event in that period, showing association with age and CKD.

Bibliographic References

  • Dégano I.R., Elosua R., Marrugat J. Epidemiología del síndrome coronario agudo en España: estimación del número de casos y la tendencia de 2005 a 2009. Rev Esp Cardiol. 2013, 66:472-481.
  • Gruntzig A.R., Senning A., Siegenthaler W.E. Nonoperative dilatation of coronary artery stenosis: Percutaneous transluminal coronary angioplasty. N Eng J Med. 1979, 301:61-68.
  • Windecker S., Kolh P., Alfonso F., Collet J.P., Cremer J., Falk V., et al. ESC/EACTS Guidelines on myocardial revascularization. The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2014, 35:2541-2569.
  • Wilson K., Gibson N., Willan A., Cook D. Effect of smoking cessation on mortality after myocardial infarction. Meta-analysis of cohort studies. Arch Intern Med. 2000, 160:939-944.
  • Serrano M., Madoz E., Ezpeleta I., San Julián B., Amézqueta C., Pérez-Marco J.A., et al. Abandono del tabaco y riesgo de nuevo infarto en pacientes coronarios: estudio de casos y controles anidado. Rev Esp Cardiol. 2003, 56:445-451.
  • Granger C.B., Goldberg R.J., Dabbous O., Pieper K.S., Eagle K.A., Cannon C.P., et al. Predictors of hospital mortality in the Global Registry of Acute Events. Arch Intern Med. 2003, 63:2345-2353. Global Registry of Acute Coronary Events Investigators.
  • Cannon C.P., Braundwald E., McCabe C.H., Rader D.J., Rouleau J.L., Belder R., et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004, 350:1495-1504.
  • Schwartz G.G., Olsson A.G., Ezekowitz M.D., Ganz P., Oliver M.F., Waters D., et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: The MIRACL study: A randomized controlled trial. JAMA. 2001, 285:1711-1718. Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators.
  • Gibbons R.J., Balady G.J., Timothy J., Chaitman B., Fletcher G., Froelicher V., et al. ACC/AHA 2002 Guideline update for the management of patients with chronic stable angina. Summary article. Circulation. 2002, 106:1883-1892.
  • Simpson C.R., Buckley B.S., McLernon D.J., Sheik A., Murphy A., Hannaford P.C. Five-years prognosis in an incident cohort of people presenting with acute myocardial infarction. PLoS ONE. 2011, 6:e26573.
  • De Velasco J.A., Cosín J., López-Sendón J.L., de Teresa E., de Oya M., Sellers G. Nuevos datos sobre la prevención secundaria del infarto de miocardio en España. Resultados del estudio PREVESEII. Rev Esp Cardiol. 2002, 55:801-809. En representación del Grupo de Investigadores del Estudio PREVESE II.
  • Solís C.A., Muñoz M. Prevalencia de factores de riesgo cardiovascular en pacientes evaluados por dolor torácico. Rev Mex Cardiol. 2007, 18:109-118.
  • Yusuf S., Hawken S., Ounpuu S., Dans T., Avezum A., Lanas F., et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): Case-control study. Lancet. 2004, 364:937-952. INTERHEART Study Investigators.
  • O'Donnell M.J., Xavier D., Liu L., Zhang H., Chin S.L., Rao-Melacini P., et al. Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): A case-control study. Lancet. 2010, 376:112-123. INTERSTROKE investigators.
  • De Velasco J.A., Cosín J., Lopez-Sendón J.L., de Teresa E., de Oya M., Carrasco J.L., et al. La prevención secundaria del infarto de miocardio en España. Estudio PREVESE. Rev Esp Cardiol. 1997, 50:406-415. en nombre del grupo de investigadores del estudio PREVESE.
  • A European Society of Cardiology survey on a secondary prevention of coronary heart disease: Principal results. Eur Heart J. 1997, 18:569-1582. EUROASPIRE Study Group.
  • De Velasco J.A., Llargués E., Fitó R., Sala J., del Río A., de los Arcos E. Prevalencia de los factores de riesgo y tratamiento farmacológico al alta hospitalaria en el paciente coronario. Resultados de un registro multicéntrico nacional (Programa 3C). Rev Esp Cardiol. 2001, 54:159-168.
  • Tranche S., López I., Mostaza J.M., Soler B., Mantilla M.T., Taboada M., et al. Control de factores de riesgo coronario en prevención secundaria: estudio PRESENAP. Med Clin (Barc). 2006, 127:765-769. en representación de los investigadores del estudio PRESENAP.
  • Kotseva K., Word D., de Backer D., Pyörälä K., Keil U. Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIREI, II, and III surveys in eight European countries. Lancet. 2009, 373:929-940. for the EUROASPIRE Study Group.
  • Aguado Romero M.J., Márquez Calderón S., Buzón Barrera M.L. Diferencias entre mujeres y varones en el acceso a procedimientos cardiovasculares intervencionistas en los hospitales públicos de Andalucía. Rev Esp Cardiol. 2006, 59:785-793. por los investigadores del grupo UPM-IRYSS-Andalucía.
  • Instituto Galego de Estadística [sede Web]. Población segundo sexo e grandes grupos de idade. Santiago de Compostela: Instituto Galego de Estadística; 2011 [consultado 21 Abr 2014]. Disponible en: . http://www.ige.eu/web/mostrar_actividade_estatistica.jsp.
  • Pendyala L.K., Torguson R., Loh J.P., Kitabata H., Minha S., Badr S., et al. Comparison of adverse outcomes after contemporary percutaneous coronary intervention in women versus men with acute coronary syndrome. Am J Cardiol. 2013, 111:1092-1098.
  • Badimon L., Vilahur G. Enfermedad aterotrombótica coronaria: avances en el tratamiento antiplaquetario. Rev Esp Cardiol. 2008, 61:501-513.
Data source: Dialnet